Glycopyrrolate
Cuvposa, GLYRX-PF, Glycate
Anticholinergic
NADAC/unit
$0.1028
No Shortage
Tier 1: 45.6%
PA Req: 15.5%
35 Manufacturers
53 ANDAs
vs. brand Cuvposa: Generic saves up to 99% per unit
Market Intelligence
2026-02-04 Class III Recall: NOVADOZ PHARMACEUTICALS LLC
2023-06-28 Class III Recall: Aurolife Pharma, LLC
2023-06-14 Class III Recall: HF Acquisition Co LLC
2023-03-08 Class II Recall: Accord Healthcare, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
Generic Manufacturers
ACCORD HEALTHCARE INCAJENAT PHARMACEUTICALS LLCALEMBIC PHARMACEUTICALS LTDAMERICAN REGENT INCAMNEAL EU LTDANNORA PHARMA PRIVATE LTDAPPCO PHARMA LLCAUROBINDO PHARMA LTDBIONPHARMA INCCAPLIN STERILES LTDCASPER PHARMA LLCCHARTWELL RX SCIENCES LLCEXELA PHARMA SCIENCES LLCFRESENIUS KABI USA LLCGLAND PHARMA LTDGRANULES PHARMACEUTICALS INCHIKMA FARMACEUTICA (PORTUGAL) SAHIKMA PHARMACEUTICALS USA INCLGM PHARMA SOLUTIONS LLCMEITHEAL PHARMACEUTICALS INCMERZ PHARMACEUTICALS LLCMSN LABORATORIES PRIVATE LTDNATCO PHARMA LTDOMNIVIUM PHARMACEUTICALS LLCOXFORD PHARMACEUTICALS LLCPH HEALTH LTDPIRAMAL CRITICAL CARE INCPRINSTON PHARMACEUTICAL INCQUAGEN PHARMACEUTICALS LLCREGCON HOLDINGS LLCRISING PHARMA HOLDINGS INCSAGENT PHARMACEUTICALSSANDOZ INCSCIEGEN PHARMACEUTICALS INCSOMERSET THERAPEUTICS LLCSUN PHARMACEUTICAL INDUSTRIES LTDSUVEN PHARMACEUTICALS LTDUMEDICA LABORATORIES PRIVATE LTDVELZEN PHARMA PVT LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.